CLAUDIA GORE: Open Payments
NPI 1700429164 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,863 in 102 payments from 15 companies in 2025. Trend: 2023 $2,380 · 2024 $2,175 · 2025 $1,863
Food & beverage: $1,752Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $281 |
| Neurocrine BioSciences, Inc. | 9 | $236 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $215 |
| ABBVIE INC. | 27 | $211 |
| Teva Pharmaceuticals USA, Inc. | 8 | $210 |
| Vanda Pharmaceuticals Inc. | 7 | $138 |
| Corium, LLC | 5 | $117 |
| Lundbeck LLC | 5 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $96 |
| Janssen Pharmaceuticals, Inc | 4 | $82 |
Products named: REXULTI, INGREZZA, CAPLYTA, VRAYLAR, FANAPT, Azstarys, UZEDY, TRINTELLIX.
Industry payments across AL — which companies pay providers there.
